Physician profile
Sean Su
NPI 1760597405
$6,087.38
in general payments reported to CMS, 2019-2025
35 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,167 · 2020: $623 · 2021: $702 · 2022: $285 · 2023: $496 · 2024: $330 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,310.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $973.78 | 2019-2024 | Airsupra, Breztri |
| Amgen INC. | $465.55 | 2019-2020 | |
| Glaxosmithkline, LLC. | $450.27 | 2019-2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $400.83 | 2025 | |
| Allergan, INC. | $373.79 | 2019-2020 | |
| Genentech USA, INC. | $267.05 | 2019-2020 | |
| Genzyme Corporation | $239.76 | 2019-2020 | |
| Abbott Laboratories | $227.48 | 2023 | Freestyle Libre 3 |
| Harmony Biosciences LLC | $198.75 | 2021-2023 | Wakix |
| Abbvie INC. | $186.24 | 2021-2025 | |
| Pfizer INC. | $162.51 | 2019-2023 | |
| Novo Nordisk INC | $151.46 | 2022-2024 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $151.08 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.91 | 2019-2021 | |
| Revance Therapeutics, INC. | $129.16 | 2024 | Daxxify |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $125.05 | 2021 | |
| United Therapeutics Corporation | $121.44 | 2019 | |
| Shire North American Group INC | $121.41 | 2019 | |
| Zimmer Biomet Holdings, INC. | $120.56 | 2019 | |
| Merz North America, INC. | $118.03 | 2019 | |
| Redhill Biopharma INC. | $116.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $116.31 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $113.40 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $111.32 | 2019 | |
| Sunovion Pharmaceuticals INC. | $108.28 | 2019 | |
| Lilly USA, LLC | $90.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.45 | 2022 | |
| Exact Sciences Corporation | $56.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Gilead Sciences, INC. | $47.69 | 2021-2022 | |
| Mckesson Medical-Surgical, INC. | $27.80 | 2025 | |
| Daiichi Sankyo INC. | $22.89 | 2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $19.51 | 2021 | |
| Axsome Therapeutics, INC. | $18.90 | 2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $15.61 | 2022 | |
| Vanda Pharmaceuticals INC. | $13.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.